Hypoglycemic Agent Screen, Serum
Use
This test is useful for the evaluation of suspected insulinoma, characterized by hypoglycemia and increased serum insulin concentration. It also aids in detecting drugs that stimulate insulin secretion, including first- and second-generation sulfonylureas, meglitinides, and thiazolidinediones. The test is not intended for therapeutic drug monitoring but could be used to monitor compliance with medications.
Special Instructions
Not provided.
Limitations
The test requires serum collected during or close to the time of a hypoglycemic episode. Drugs will not be detected if blood is drawn when glucose is normal in non-diabetic patients. The test does not detect drugs that lower glucose through mechanisms not involving insulin. Also, the screen does not cover the first-generation sulfonylurea acetohexamide, as well as certain thiazolidinediones that do not induce hypoglycemia.
New York Approved
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
LOINC Codes
- 68318-5 - Hypoglycemics pnl SerPl
- 48329-7 - chlorproPAMIDE SerPl Ql
- 21566-5 - TOLAZamide SerPl Ql
- 21567-3 - TOLBUTamide SerPl Ql
- 48325-5 - Glimepiride SerPl Ql
- 48326-3 - glipiZIDE SerPl Ql
- 48327-1 - glyBURIDE SerPl Ql
- 48328-9 - Repaglinide SerPl Ql
- 49487-2 - Nateglinide SerPl Ql
- 100351-6 - Pioglitazone SerPl Ql
- 100352-4 - Rosiglitazone SerPl Ql
Result Turnaround Time
2-6 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1.5 mL
Minimum Volume
0.5 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Patient Preparation
Specimen must be collected during an episode of hypoglycemia.
Causes for Rejection
Serum gel/SST are not acceptable
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 28 days |
| Frozen | 28 days |